OROXYLIN A

Details

Stereochemistry	ACHIRAL
Molecular Formula	C16H12O5
Molecular Weight	284.2635
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=C(O)C=C2OC(=CC(=O)C2=C1O)C3=CC=CC=C3

InChI

InChIKey=LKOJGSWUMISDOF-UHFFFAOYSA-N

InChI=1S/C16H12O5/c1-20-16-11(18)8-13-14(15(16)19)10(17)7-12(21-13)9-5-3-2-4-6-9/h2-8,18-19H,1H3

HIDE SMILES / InChI

Molecular Formula	C16H12O5
Molecular Weight	284.2635
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27539056 | https://www.ncbi.nlm.nih.gov/pubmed/28594405 | https://www.ncbi.nlm.nih.gov/pubmed/23371806

Oroxylin A is a flavonoid compound, one of the main components extracted from Scutellariae radix. It possess a broad spectrum of pharmacological effects, especially anti-cancer, anti-inflammatory and neuroprotective activity. Oroxylin A inactivated HIF1α and reprogrammed fatty acid metabolism of HCT116 cells, decreasing intracellular fatty acid level and enhancing fatty acid oxidation. Oroxylin A improves attention-deficit hyperactivity disorder-like behaviors in spontaneously hypertensive rats via enhancement of dopamine neurotransmission and not modulation of GABA pathway as previously reported. Importantly, the present study indicates the potential therapeutic value of oroxylin A in the treatment of attention-deficit hyperactivity disorder. Both in vitro and in vivo study showed that oroxylin A possesses low toxicity, but the field was just limited in cancer research.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
BDNF signaling pathway 1 Target ID: WP2380 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25218897	Activator 1430
dopamine uptake 14 Target ID: GO:0090494 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23371806	Inhibitor 8297
Fatty acid metabolism 1 Target ID: map01212 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28594405	Modulator 828

Conditions

Condition	Modality	Highest Phase	Product
Attention deficit hyperactivity disorder 68 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23371806	Primary	Preclinical	Unknown Approved Use Unknown
Hepatoma 3 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28726775	Primary	Preclinical	Unknown Approved Use Unknown
Colorectal cancer 101 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28594405	Primary	Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Liquid chromatography with tandem mass spectrometry for the simultaneous determination of baicalein, baicalin, oroxylin A and wogonin in rat plasma.	2006 Dec 5	16893689
Effect of the flavonoid, oroxylin A, on transient cerebral hypoperfusion-induced memory impairment in mice.	2006 Nov	17174385
Pharmacokinetics of baicalein, baicalin and wogonin after oral administration of a standardized extract of Scutellaria baicalensis, PF-2405 in rats.	2007 Feb	17366750
New dihydrochalcones and anti-platelet aggregation constituents from the leaves of Muntingia calabura.	2007 Jun	17516329
The ameliorating effect of oroxylin A on scopolamine-induced memory impairment in mice.	2007 May	17196405
Synthesis and biological evaluation of novel 8-aminomethylated oroxylin A analogues as alpha-glucosidase inhibitors.	2008 Mar 1	18255289
Oroxylin A induces G2/M phase cell-cycle arrest via inhibiting Cdk7-mediated expression of Cdc2/p34 in human gastric carcinoma BGC-823 cells.	2008 Nov	18957166
The effects of acute and repeated oroxylin A treatments on Abeta(25-35)-induced memory impairment in mice.	2008 Oct	18620712
[Flavonoids from Scutellaria baicalensis and their bioactivities].	2009 Oct 18	19829679
Synergistic effect of 5-fluorouracil and the flavanoid oroxylin A on HepG2 human hepatocellular carcinoma and on H22 transplanted mice.	2010 Feb	19585117
Anti-pruritic effect of baicalin and its metabolites, baicalein and oroxylin A, in mice.	2010 Jun	20453872
4'-bromo-5,6,7-trimethoxyflavone represses lipopolysaccharide-induced iNOS and COX-2 expressions by suppressing the NF-κB signaling pathway in RAW 264.7 macrophages.	2012 Jan 1	22101131

Patents

Sample Use Guides

In Vivo Use Guide

Rat: 1, 5 and 10 mg/kg

Route of Administration: Intraperitoneal

In Vitro Use Guide

Oroxylin A was able to inhibit glucose uptake and the release of lactate of human hepatocellular carcinoma HepG2 cells at relatively mild concentrations (12.5–50 uM) without inducing severe apoptosis (mostly 8.78%).

Substance Class	Chemical Created by `admin` on `Sat Dec 16 03:21:11 GMT 2023` Edited by `admin` on `Sat Dec 16 03:21:11 GMT 2023`
Record UNII	53K24Z586G
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

OROXYLIN A

Common Name

English

BAICALEIN 6-METHYL ETHER

Brand Name

English

OROXYLIN

Common Name

English

5,7-DIHYDROXY-6-METHOXYFLAVONE

Systematic Name

English

5,7-DIHYDROXY-6-METHOXY-2-PHENYL-4H-1-BENZOPYRAN-4-ONE

Systematic Name

English

5,7-DIHYDROXY-6-METHOXY-2-PHENYLCHROMEN-4-ONE

Systematic Name

English

FLAVONE, 5,7-DIHYDROXY-6-METHOXY-

Systematic Name

English

6-METHOXYBAICALEIN

Common Name

English

OROXYLIN A [MI]

Common Name

English

Code System Code Type Description

FDA UNII

53K24Z586G